Orally administered heparins prevent arterial thrombosis in a rat model

Summary

Our previous studies demonstrated that orally administered heparins prevent thrombosis in a rat jugular vein thrombosis model, where bovine unfractionated heparin (UFH) and the low molecular weight heparin tinzaparin reduced thrombotic incidence by 50% at 7.5 and 0.1 mg/kg, respectively. Our objectives were to determine if similar antithrombotic effects of oral heparin could be observed in an arterial thrombosis model. In this model, filter paper soaked in 30% ferric chloride was applied to the exposed rat carotid artery. A flowmeter recorded blood flow over a 60 min period determining time when the thrombus began forming (TTB) and time till occlusion (TTO). Immediately following, the thrombus was removed, dried and weighed 24 h later. Bovine UFH (7.5 mg/kg), tinzaparin (0.1 mg/kg) or saline was administered by stomach tube at 2, 5 and 25 h prior to thrombus initiation. TTB was significantly increased when UFH was given at 5 and 25 h but not 2 h prior, and when tinzaparin was given at 5 but not 2 or 25 h prior compared to rats given oral saline. TTO was significantly increased for both UFH and tinzaparin when given 5 and 25 h but not 2 h prior (one-way ANOVA). There was no difference in TTO and TTB between UFH and tinzaparin treated groups. A trend in reduction in thrombus weight was observed for UFH at 5 and 25 h prior and tinzaparin at 5 h prior to thrombus initiation (one-way ANOVA). Although no significant changes were observed in activated partial thromboplastin times, Heptest or anti-Xa activity from plasma of heparin treated rats, endothelial heparin concentrations were significantly greater than controls for UFH at 5 h and for tinzaparin at 2, 5, and 24 h. Thus, heparins administered by the oral route are effective antithrombotic agents in arterial as well as venous models.

Keywords

Arterial thrombosis - unfractionated heparin - tinzaparin - oral - rats

• References

• 1 Berkowitz SD, Kosutic G, Marder VJ. et al. Heparin administered orally via a novel carrier system (SNAC) is comparable to SC heparin when used to prevent venous thromboembolic events following elective total hip arthroplasty. Thromb Haemost 1999; Suppl: 492-3.
• 2 Jaques LB, Hiebert LM, Wice SM. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J Lab Clin Med 1991; 117 (02) 122-30.
• 3 Hiebert LM, Wice SM, Ping T. et al. Tissue distribution and antithrombotic activity of unlabeled or ¹⁴C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route. Can J Physiol Pharmacol 2000; 78: 307-20.
• 4 Hiebert LM, Wice SM, Jaques LB. Antithrombotic activity of oral unfractionated heparin. J Cardiovasc Pharmacol 1996; 28: 26-9.
• 5 Hiebert LM, Ping T, Wice SM. Antithrombotic activity of orally administered low molecular weight heparin (logiparin) in a rat model. Haemostasis 2000; 30: 196-203.
• 6 Hiebert LM, Wice SM, Ping T. et al. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Thromb Haemost 2001; 85: 114-8.
• 7 Hiebert LM. Evidence that Orally Administered Heparins are Absorbed. In: Thrombosis from Bench to Bedside (in press)
• 8 Mitchell RN, Cotran RS. Hemodynamic Disorders. Thrombosis and Shock. In: Robbins Basic Pathology; Saunders WB Co: 2002: 113-38.
• 9 Lockyer S, Kambayashi J. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J Cardiovasc Pharmacol 1999; 33: 718-25.
• 10 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
• 11 Leadley RJ, Morgan SR, Bentley R. et al. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation Factor Xa. J Cardiovasc Pharmacol 2003; 34: 791-9.
• 12 Hiebert LM, Jaques LB. The observation of heparin on endothelium after injection. Thromb Res 1976; 08: 195-204.
• 13 Jaques LB, Wice SM, Hiebert LM. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. J Lab Clin Med 1990; 115 (04) 422-32.
• 14 Rivera TM, Leone BA, Paton DR. et al. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm Res 1997; 14: 1830-4.
• 15 Lee Y, Kim SH, Byun Y. Oral delivery of new heparin derivatives in rats. Pharm Res 2000; 17: 1259-64.
• 16 Jiao Y, Ubrich N, Marchand-Arvier M. et al. In vitro and in vivo evaluation of oral heparinloaded polymeric nanoparticles in rabbits. Circulation 2002; 105: 230-5.
• 17 Engelberg H. Orally ingested heparin is absorbed in humans. Clin Appl Thromb Hemost 1995; 01 (04) 283-5.
• 18 Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92.
• 19 Hiebert LM. Oral heparins. Clin Lab 2002; 48: 111-6.
• 20 Lewis SD, Ng AS, Lyle EA. et al. Inhibition of thrombin by peptides containing lysyl-a-keto carbonyl derivatives. Thromb Haemost 1995; 74: 1107-12.